(Q41745131)

8 October 2017

1 reference

title

Current immunotherapy in multiple sclerosis (English)

1 reference

8 October 2017

1 reference

Bashir K

1

1 reference

PubMed ID

9553777

8 October 2017

Whitaker JN

series ordinal

2

1 reference

8 October 2017

1 February 1998

1 reference

Immunology & Cell Biology

8 October 2017

1 reference

8 October 2017

76

1 reference

8 October 2017

1

1 reference

8 October 2017

55-64

1 reference

Immunosuppressive therapy of autoimmune diseases

8 October 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00714.X

Rationale for immunotherapy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00714.X

Defining the clinical course of multiple sclerosis: Results of an international survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00714.X

Exacerbations of multiple sclerosis in patients treated with gamma interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00714.X

Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00714.X

Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00714.X

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00714.X

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00714.X

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00714.X

A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00714.X

A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00714.X

Intravenous methylprednisolone for multiple sclerosis in relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00714.X

A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00714.X

The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00714.X

Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00714.X

Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00714.X

Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00714.X

Introductory remarks: immunosuppressive and immunomodulating drugs, where and how do they act?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00714.X

Randomised double blind controlled trial of cyclosporin in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00714.X

Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00714.X

Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00714.X

Low-dose oral methotrexate in chronic progressive multiple sclerosis: analyses of serial MRIs

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00714.X

Immunopharmacology. Immunomodulation and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00714.X

Overview of azathioprine treatment in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00714.X

Long-term safety of azathioprine therapy in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00714.X

Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00714.X

Cladribine in treatment of chronic progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00714.X

The treatment of chronic progressive multiple sclerosis with cladribine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00714.X

Influence of FK 506 (tacrolimus) on circulating CD4+ T cells expressing CD25 and CD45RA antigens in 19 patients with chronic progressive multiple sclerosis participating in an open label drug safety trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00714.X

Total lymphoid irradiation in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00714.X

Combination total lymphoid irradiation and low-dose corticosteroid therapy for progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00714.X

An open-trial evaluation of mitoxantrone in the treatment of progressive MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00714.X

Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00714.X

An open trial of OKT3 in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00714.X

Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00714.X

Plasma exchange and intravenous immunoglobulin treatment of neuromuscular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00714.X

Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00714.X

Modulation of immunity in multiple sclerosis: a double-blind levamisole-placebo controlled study in 85 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00714.X

A placebo-controlled trial of isoprinosine in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00714.X

Acyclovir treatment of relapsing-remitting multiple sclerosis. A randomized, placebo-controlled, double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00714.X

The use of monoclonal antibodies to achieve immunological tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00714.X

10.1046/J.1440-1711.1998.00714.X

21 January 2018

Identifiers

DOI

1 reference

8 October 2017

1 reference

PubMed ID

9553777